The Latest Cardiac and Vascular News
DURHAM, N.C., May 23, 2018 /PRNewswire/ — A 24-month update on the DESSOLVE III trial of the MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent) was presented this week at EuroPCR 2018, an international congress of interventional cardiovascular medicine researchers and clinicians held in Paris, France. Data were presented by William Wijns, M.D., Ph.D., of The Lambe Institute for […]
“This preclinical demonstration that stent deployment of microcrystalline drug in combination with a rapidly absorbable polymer, such as with MiStent, results in more uniform drug dosing that could lead to more rapid and uniform healing across the treated segment,” said David Kandzari, M.D., Director of Interventional Cardiology and Chief Scientific Officer, Piedmont Heart Institute, Atlanta. LEXINGTON, Mass.–(BUSINESS […]
DURHAM, N.C., Jan. 9, 2018 /PRNewswire/ — Micell Technologies announced the recent online publication of five-year data from the DESSOLVE I and II trials. The report, “Long-term clinical outcomes of a crystalline sirolimus-eluting coronary stent with a fully bioabsorbable polymer coating: five-year outcomes from the DESSOLVE I and II trials” was peer reviewed and published by the […]
DURHAM, N.C., Dec. 6, 2017 /PRNewswire/ — Micell Technologies, Inc. announced that The Lancet has published data from the DESSOLVE III clinical trial. The study met its primary endpoint, showing non-inferior safety and effectiveness outcomes in a complex patient population for the MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent) versus the Xience® Everolimus Eluting Coronary Stent System (Xience). The […]
Micell raises $62m for MiStent SES SEPTEMBER 19, 2017 BY BRAD PERRIELLO, Drug Delivery Business News Micell Technologies said last week that it raised a debt-and-equity round worth nearly $62 million from a syndicate of 51 unnamed investors. Paris-based Micell makes the MiStent SES sirolimus-eluting absorbable polymer coronary stent, designed to treat coronary artery disease. The company, which reported a […]
